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Abstract The polymorphism at residue 129 of the human
PRNP gene modulates disease susceptibility and the clinico-
pathological phenotypes in human transmissible spongiform
encephalopathies. The molecular mechanisms by which the eﬀect
of this polymorphism are mediated remain unclear. It has been
shown that the folding, dynamics and stability of the physiolog-
ical, a-helix-rich form of recombinant PrP are not aﬀected by
codon 129 polymorphism. Consistent with this, we have recently
shown that the kinetics of amyloid formation do not diﬀer be-
tween protein containing methionine at codon 129 and valine at
codon 129 when the reaction is initiated from the a-monomeric
PrPC-like state. In contrast, we have shown that the misfolding
pathway leading to the formation of b-sheet-rich, soluble oligo-
mer was favoured by the presence of methionine, compared with
valine, at position 129. In the present work, we examine the eﬀect
of this polymorphism on the kinetics of an alternative misfolding
pathway, that of amyloid formation using partially folded PrP
allelomorphs. We show that the valine 129 allelomorph forms
amyloids with a considerably shorter lag phase than the methio-
nine 129 allelomorph both under spontaneous conditions and
when seeded with pre-formed amyloid ﬁbres. Taken together,
our studies demonstrate that the eﬀect of the codon 129 polymor-
phism depends on the speciﬁc misfolding pathway and on the ini-
tial conformation of the protein. The inverse propensities of the
two allelomorphs to misfold in vitro through the alternative olig-
omeric and amyloidogenic pathways could explain some aspects
of prion diseases linked to this polymorphism such as age at on-
set and disease incubation time.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
The human PrP gene (PRNP) has two common allelic forms
that encode either methionine or valine at codon 129. This
polymorphism is a key determinant of susceptibility to spo-
radic [1] and acquired [2,3] prion diseases, and may aﬀect
age at onset [4–6]. An understanding of the role of this poly-
morphism as a powerful genetic modiﬁer may provide clues
as to the molecular mechanisms that mediate prion propaga-
tion. One approach is to study the folding of the two allelic
variants of recombinant human PrP in vitro. Four major
routes of folding denatured, disulphide-oxidized PrP in vitro
have been described [7–10] (see Fig. 1). The ﬁrst, which is ex-
tremely rapid under near-neutral, non-denaturing conditions,
produces an a-helix-rich, soluble, monomeric form that is be-
lieved to resemble the physiological form. It has been shown
that the thermodynamic stability of this form is not aﬀected
by the codon 129 polymorphism [11]. NMR structure analysis
has been used to investigate the structural basis of inherited
human transmissible spongiform encephalopathies and
showed that only part of the disease-related amino acid
replacements lead to reduced stability of the cellular form of
PrP [12]. Recently, the three-dimensional structure of the
monomeric, Val129 form of human PrP was determined [13],
from which it was concluded that the polymorphism at codon
129 has no measurable eﬀect on the folding, dynamics and sta-
bility of normal cellular PrP. The second major route of fold-
ing, favoured at low pH under moderately denaturing
conditions and high PrP concentrations, results in the forma-
tion of a soluble, oligomeric form that shows signiﬁcant resis-
tance to proteinase K and matures over time to become
dominated by b-sheets [8,9]. We have recently shown that
the kinetics of the b-oligomer formation is aﬀected by the res-
idue encoded at position 129. We showed that Met129 has a
higher propensity to oligomerize than Val129 and that the fur-
ther maturation of the oligomers was more rapid for the
Met129 variant than the Val129 variant [9].
The third major pathway of in vitro folding produces high
molecular weight multimers that aggregate to form amyloid ﬁ-
bres and is favoured under moderately denaturing conditions,
neutral pH and with agitation [8,14]. This form is partially sen-
sitive to proteinase K digestion. Signiﬁcantly, it has been re-
ported, recently, that the amyloids generated through this
third pathway from recombinant mouse PrP were infectious
and produces transmissible disease when inoculated into trans-
genic mice [15]. This result is a major milestone in that it ap-
pears to conﬁrm the ‘‘protein only’’ hypothesis in
mammalian prion diseases [15,16]. It also suggests that the
amyloids form of recombinant PrP and/or other misfolded
intermediates may represent the infectious entity in TSE dis-
eases. Recently, we have found that the polymorphism at co-
don 129 has no measurable eﬀect on the amyloid
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accumulation when the reaction is initiated from the a-helical
monomeric form [10] (see pathway 3 in Fig. 1). This is in con-
trast to the substantial eﬀect that this common polymorphism
can exert on the formation of soluble b-oligomer when the mis-
folding is initiated from denatured state (see pathway 2 in Fig. 1)
[9]. This suggests that the conformational transitions, in which
residues at position 129 contribute to signiﬁcant free energy
changes, are likely to be conﬁned to more disordered states
than those shared by the a-monomers of the PrP [10]. In order
to test this, we decided to analyse the eﬀect of the polymor-
phism at codon 129 on the pathway four as depicted in Fig.
1, by initiating the amyloid formation from a partially folded
state and that is under both spontaneous and seeded condi-
tions. The rational behind this is to allow the two allelomorphs
to explore freely the misfolding landscape permitted under
amyloid forming conditions.
2. Materials and methods
2.1. Preparation of recombinant human prion protein allelomorphs
The recombinant human PrP90–231 proteins were prepared and puri-
ﬁed as previously described [9]. Brieﬂy, the genomic DNA encoding
methionine/valine at codon 129 of PRNP gene was extracted from
the blood of a heterozygote individual using standard phenol–chloro-
form methods. The fragment of the PRNP gene spanning codon 90
through 231 was ampliﬁed and cloned into the pTrcHis2B vector that
incorporated a C-terminal His-tag (Invitrogen life technologies, Pais-
ley, UK) according to the manufacturers instructions. The identity
of human PrP clones was conﬁrmed by sequencing with the BigDye
Terminator v3.0 on ABI-Prism 3100 Genetic Analyzer (Applied Bio-
systems). The clones corresponding to PrP90–231 with Met129 or
Val129 were identiﬁed by comparison with human PrP clones available
in the databases (Accession Nos.: M13667, P04156). The expression of
both recombinant PrP variants was done in Escherichia coli and the
puriﬁcation was performed as previously described [9]. Stocks of highly
puriﬁed proteins were stored in 6 M guanidine hydrochloride contain-
ing 50 mM Tris–HCl, pH 7.2.
2.2. Amyloid reactions, thioﬂavin T assay and kinetic analysis
Time course study of amyloid formation of recombinant human
PrP90–231 was carried out as previously described [8] by monitoring thi-
oﬂavin T (ThT) ﬂuorescence. Brieﬂy, proteins in 6 M guanidine hydro-
chloride were diluted to a ﬁnal concentration of 35 lM in phosphate
buﬀered saline, pH 7.2, containing 3 M urea, 0.02% azide and a ﬁnal
concentration of 1 M guanidine hydrochloride. Samples were incu-
bated at 37 C under continuous shaking at 600 rpm on a Delﬁa plate
shaker in 1.5 ml Eppendorf tubes. To mimic the situation in heterozy-
gote individuals, methionine 129 and valine 129 variants were mixed at
1:1 molar ratio. The ﬁnal protein concentration was kept at 35 lM. In
the homologous and heterologous seeding experiments, an aliquot of
preformed ﬁbrils was taken from the stationary phase and considered
to contain 100% seeds, this was then used to inoculate freshly prepared
amyloid reaction at a ﬁnal seed concentration of 1%.
The kinetics of amyloid formation were analysed by ﬁtting time-
dependent changes in ThT ﬂuorescence of samples to the following sig-
moidal equation using non-linear, least squares analysis (GraphPad
Prism vs. 4.01).
F ThT ¼ A=ð1þ eðBðttiÞÞÞ; ð1Þ
where FThT is the ﬂuorescence intensity of ThT, A is the ThT ﬂuores-
cence intensity in the post-transition plateau, ti is the inﬂection point,
i.e., the midpoint of the transition region, B (h1) is the amyloid
growth rate constant, and t is the time in hour. The lag time (tlag) of
amyloid formation was calculated by extrapolation of the linear region
of the sigmoidal transition phase of ThT ﬂuorescence to the abscissa
intercept [17].
2.3. Size-exclusion high performance liquid chromatography
Rapid refolding of proteins into a-monomeric form was carried out
by size-exclusion HPLC as previously described [9] with the following
modiﬁcations: Proteins, in 100 ll volume at 5 mg/ml from unfolded
state in 6 M guanidine hydrochloride, 50 mM Tris–HCl, pH 7.2, were
injected onto TSK-Gel SWXL G3000 HPLC column, 7.8 · 300 mm
(Phenomenex, Macclesﬁeld, UK), equilibrated in 50 mM sodium ace-
tate, pH 5.5, 150 mM sodium chloride, 1 M urea and 0.02% azide.
The peak corresponding to monomeric proteins was manually col-
lected and the folding of the proteins was assessed by circular dichro-
ism (CD). All HPLC separations were performed at room temperature
with a ﬂow rate of 1 ml/min by means of a Perkin–Elmer HPLC system
composed of a Binary LC pump 250 and a Diode array detector 235C
controlled by Total Chrome software version 6.2 (Perkin–Elmer, Seer
Green, UK), through a PE Nelson 600 series link. The eluent was mon-
itored by UV absorption at 280 nm.
2.4. Circular dichroism and Fourier transform infra-red spectroscopy
CD spectra were recorded using a Jasco-720 spectrometer at 37 C in
the amyloid buﬀer (phosphate buﬀered saline, pH 7.2, containing 3 M
urea, 0.02% azide and a ﬁnal concentration of 1 M guanidine hydro-
chloride) at around 35 lM protein concentration using the following
parameters: Cell path 0.1 cm, speed 55 nm/s, band width 1.0 nm, reso-
lution 0.5 nm and response 4 s. Four individual scans were averaged
and the buﬀer spectra were subtracted. Fourier transform infra-red
spectroscopy (FTIR) spectra were collected by means of a Bruker Ten-
sor 27 FTIR instrument (Bruker Optics, Billerica, MA) equipped with
a MCT detector cooled with liquid nitrogen. The amyloids were dia-
lyzed against 10 mM Na-acetate buﬀer (pH 5.5), 10 ll of each sample
was loaded into BioATRcell II, 128 scans at 2 cm1 resolution were
collected under constant purging with nitrogen, corrected for water va-
pours and background spectra of buﬀer were subtracted.
2.5. Negative staining and transmission electron microscopy
Aliquots of 3 ll were taken from samples containing amyloid ﬁbrils as
judged from ThT ﬂuorescence, loaded onto carbon-coated, glow-
discharged 400-mesh copper grids, blotted, negatively stained with 1%
Fig. 1. Model of the multiple folding pathways of recombinant human
PrP in vitro (adapted from Tahiri-Alaoui and James [10]). Various
routes of folding of recombinant, disulphide-oxidized PrP have been
discussed in the literature (Baskakov et al. [7,8]): pathway 1, from the
denatured state to a-helical monomeric state; pathway 2, from the
denatured state to PK-resistant oligomeric form [9]; pathway 3, from
a-helical monomeric state to amyloid form [10]; pathway 4, from
partially unfolded state to multimeric aggregate and hence to amyloid
form. The present work describes the misfolding of recombinant
human PrP90–231 through pathway 4 in the context of the polymor-
phism at codon 129.
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uranyl acetate, air dried and then viewed in aZeiss (formerly Leo)Omega
912 electron microscope equipped with an in column charge-coupled
device camera (2048 · 2048 pixels) from Proscan, Germany [18].
3. Results
In order to gain insights into the global conformation of the
PrP allelomorphs at time zero of amyloid reaction, i.e., the
time when the proteins were diluted from 6 M guanidine
hydrochloride into the amyloid buﬀer (phosphate buﬀered sal-
ine, pH 7.2, containing 1 M guanidine hydrochloride, 3 M urea
and 0.02% azide), we performed simultaneous analyses by size
exclusion high performance liquid chromatography and CD
(Fig. 2 and inset). Aliquots of 100 ll were taken from the amy-
loid reactions and injected onto a SEC-HPLC column previ-
ously equilibrated in the same amyloid buﬀer. The Met129,
Val129 as well as the mixture (1:1) of both variants eluted with
equal retention times, i.e., 8.35 min (Fig. 2). However, when
the properly folded a-monomeric PrP was diluted into the
same amyloid buﬀer then subjected to the same SEC-HPLC
analysis, its retention time increased to 9.05 min (Fig. 2). These
diﬀerences in the retention times were indicative of conforma-
tional/aggregation diﬀerences at time zero between the starting
material used in pathway 4 as compared to that used previ-
ously to investigate pathway 3 (Fig. 1) [10]. The former has
a conformation that was most likely to be characterized by a
large hydrodynamic volume, indicating a more open structure;
though the presence of dimers in this state could not be ruled
out. CD spectra (inset in Fig. 2) of protein samples used to ini-
tiate pathway 4 were also diﬀerent from those used to initiate
pathway 3. The CD spectrum of the latter was characteristic of
an a-helix-rich conformation as indicated by the two minima
at around 210 and 222 nm. By contrast, the CD spectra of
the PrP allelomorphs used to initiate the pathway 4 in Fig. 1
were not typical of a-helix-rich proteins (inset in Fig. 2) but
were also not indicative of random coil or typical b-sheet-rich
conformation. The presence of 1 M guanidine hydrochloride
and 3 M urea in the amyloid forming buﬀer made it diﬃcult
to extract spectral information between 190 and 208 nm. How-
ever, one can conclude from the CD and SEC data that all the
PrP variants used to initiate the amyloid formation in pathway
4 of Fig. 1 had comparable levels of disordered conformation.
Therefore, any diﬀerences in the kinetics of the misfolding
behaviour would be attributed to the eﬀect of the polymor-
phism at codon 129.
CD analysis (Fig. 3A–C) revealed conformational changes
during amyloid formation through pathway 4 (Fig. 1) that oc-
curred starting from around 3 h after initiating the amyloid
reactions. The CD spectra of the two individual PrP variants
as well as in the 1:1 mixture displayed the same characteristics
up to 12 h during the amyloid reaction. There was a loose isod-
ichroic point at around 214 nm concomitant with a signiﬁcant
change of the CD signal around 222 nm, which seemed to indi-
cate a loss of a-helical conformation. This conformational
transition appeared to happen similarly between all the PrP
Fig. 2. Chromatographic and spectroscopic characterization of recombinant human PrP90–231 allelomorphs. Recombinant human PrP was expressed
with either methionine or valine at position 129 in E. coli. Proteins were fully oxidized and kept in 6 M guanidine hydrochloride buﬀered with 50 mM
Tris–HCl, pH 7.2. For amyloid reaction through pathway 4 (see Fig. 1), the PrP allelomorphs were diluted into the amyloid buﬀer (3 M urea, in PBS,
pH 7.2, 0.02% azide and the concentration of guanidine hydrochloride adjusted to 1 M), the ﬁnal protein concentration in the amyloid reaction was
35 lM. Soon after diluting the proteins in the amyloid buﬀer (time zero), 100 ll was injected onto TSK-Gel SWXL G3000 column previously
equilibrated in the same amyloid buﬀer. As a control, we have used PrP allelomorphs that were previously folded into a-monomeric from Tahiri-
Alaoui and James [9] before being diluted into the amyloid buﬀer. Because both PrP allelomorphs controls and their 1:1 mixture gave super
imposable chromatographs only the a-Met129 control is shown in the overlay. The inset shows CD spectra at time zero of amyloid reaction of PrP
allelomorphs and the control a-Met129.
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variants up to 12 h during amyloid reaction (Fig. 3A–C). How-
ever, after 24 h of amyloid reaction, the CD spectrum of the
Val129 variant was characteristic of b-sheet rich conformation
(Fig. 3D), whilst the Met129 variant and the mixture did not
appear to represent a typical b-sheet CD spectra with a single
minima at around 218 nm until 66 and 48 h, respectively (Fig.
3A and C).
In order to correlate the changes in conformation seen by
CD spectroscopy, especially, the rapid acquisition of b-sheet
structure seen in the Val129 variant as compared to the
Met129 and the 1:1 mixture, with the kinetics of ﬁbril forma-
tion we decide to monitor amyloid formation by ThT assay.
A common feature of amyloid structures is their ability to bind
dyes such as ThT. The rapid binding of ThT to amyloids is
accompanied by a dramatic increase of ﬂuorescence at around
482 nm, when excited at 455 nm. We have used this property to
monitor the accumulation of amyloids in vitro at 37 C (Fig.
4A). The formation of amyloids by both Met129 and Val129
showed a characteristic nucleation-dependent, polymerization
pattern, having an initial lag phase followed by a rapid growth
phase as measured by ThT ﬂuorescence. The length of the lag
phase, however, was signiﬁcantly diﬀerent between the two
allelomorphs; Met129 had a lag time of 52 h whilst the
Val129 allelomorph had a lag time of only 20 h. To mimic
the situation of a heterozygote individual carrying both alleles,
we analysed amyloid formation in an equimolar mixture of
Met129 and Val129 (Fig. 4B). The lag time of amyloid forma-
tion in the equimolar mixture was 31.5 h, an intermediate va-
lue compared with the unmixed proteins. Notably, in the
mixture of Met129 and Val 129 the kinetics of amyloid forma-
tion followed a single sigmoidal transition. The amyloid
growth rate constant was 0.07 h1 for both alleles individually
and also for the mixture. The total ﬂuorescence of the valine
129 and the methionine 129 variant reached a maximum
of around 3000 · 103 and 2500 · 103 counts per second,
respectively.
Given the striking diﬀerence in the lag times of spontaneous
amyloid formation between the two allelomorphs, we hypoth-
esized that the rate of nucleation was the key diﬀerence be-
tween the two forms. To test this, we examined the eﬀect of
pre-formed amyloid seeds on the kinetics of amyloid formation
in homologous as well as heterologous reactions (Fig. 5). Seed-
ing the Met129 variant with 1% Met129 amyloid decreased the
lag time of ﬁbres accumulation from 52 to 34 h. Similarly,
the homologous seeding of the Val129 variant also decreased
the lag time of ﬁbres formation from 20 to 10 h. Thus,
although the lag periods were reduced by similar proportions
by seeding in both cases, they were not rendered equal. Seeding
with heterologous amyloids had similar eﬀects on lag time as
seeding with homologous seeds (Fig. 5B). When the Met129
was seeded with the Val129 the lag time of amyloid accumula-
tion decreased from 52 to 28 h. Similarly, when the Val129 was
seeded with the Met129 the lag time of amyloid accumulation
decreased from 20 to 14 h.
In contrast to the eﬀect of seeding on lag times, the amyloid
growth rate in both homologous seeded reactions remained
similar to that of the unseeded reactions. However, seeding
with heterologous amyloid revealed that amyloid growth rates
were aﬀected by the mismatch in the polymorphic residue at
129 between the seeds and the substrates. Speciﬁcally, amyloid
growth rate of Met129 dropped from 0.07 to 0.04 h1 when
seeded with homologous versus heterologous amyloid seed,
respectively, and that of Val129 dropped to 0.05 h1 with het-
erologous seed. The shorter lag time of amyloid formation of
Fig. 3. Circular dichroism spectra of recombinant human PrP90–231 allelomorphs during amyloid formation. (A), (B) and (C) show overlay of CD
spectra of Met129, Val129 and their 1:1 mixture, respectively, during amyloid formation using the conditions described in Fig. 2. For each PrP
allelomorph, the spectra of the corresponding alfa-monomeric isoforms acquired at time zero of amyloid reaction are given for comparison to
ascertain conformational diﬀerences. (D) shows an overlay of CD spectra after 24 h of amyloid reaction to illustrate direct comparison between the
PrP allelomorphs and their 1:1 mixture as this is the time point where we see the accelerated acquisition of b-sheet structure that is not seen yet with
either M129 or the 1:1 mixture.
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Val129 versus Met129 was maintained during the homologous
and the heterologous seeding.
Amyloid ﬁbres formed under the various experimental con-
ditions showed typical characteristics of amyloids based on
transmission electron microscopy (Fig. 6A–C) and FTIR spec-
troscopy (Fig. 6D). Amyloids from both allelomorphs consist
of linear, occasionally twisted, unbranched structures (Fig.
6A–C). Based on transmission electron microscopy, the ﬁbres
from both PrP allelomorphs formed under spontaneous or
seeded conditions were morphologically indistinguishable. As
judged from FTIR, the amyloid ﬁbres produced from both
allelomorphs were also conformationally indistinguishable
(Fig. 6D). The FTIR spectra of these ﬁbres showed a major
band at 1622 cm1 and a minor broad band centred at
1535 cm1, both are characteristic of b-sheet structures with
intermolecular hydrogen bonds. A smaller band at
1693 cm1 was indicative of antiparallel b-sheets and a minor
band at 1651 cm1 was a characteristic of a-helices. Further-
more, we have used limited proteinase K digestion combined
with electrospray ionization mass spectrometry to compare
the amyloid ﬁbres from both allelomorphs (data not shown).
Consistent with our previous ﬁndings, we found that the ﬁbres
from both PrP variants displayed short PK-resistant core
[19,20].
4. Discussion
The present results demonstrate the importance of the poly-
morphism at codon 129 in modulating the formation of an
alternative misfolded form of PrP by allowing the partially
folded PrP (pathway 4, Fig. 1) to explore the pathway that
leads to amyloid formation. We have found clear diﬀerences
in the kinetics of amyloid formation between the two allelo-
morphs. The Val129 variant had a signiﬁcantly shorter lag
time prior to amyloid formation than did the Met129 variant
and this correlated well with the rapid acquisition of b-sheet
rich conformation by the Val129 allelomorph as compared
with the Met129 allelomorph and the 1:1 mixture. These data
do not contradict the observation made during the misfolding
of a-monomeric PrP into amyloids (pathway 3, Fig. 1), where
we have found no measurable eﬀects of the polymorphism at
Fig. 4. Eﬀect of the polymorphic residue at position 129 on the
kinetics of spontaneous amyloid formation of recombinant human
PrP90–231 measured by ThT ﬂuorescence. (A) Comparison of the time-
dependent change in ThT ﬂuorescence between Met129 (ﬁlled squares)
and Val129 (ﬁlled triangles) allelomorphs. The amyloid reaction was
performed at 37 C under continuous agitation (600 rpm) in 1.5 ml
tubes. The proteins were diluted from 6 M guanidine hydrochloride to
a ﬁnal concentration of 35 lM in phosphate buﬀered saline, pH 7.2,
containing 1 M guanidine hydrochloride, 3 M urea and 0.02% azide.
(B) represents a time-dependent change in ThT ﬂuorescence during
amyloid accumulation in a heterozygote-like reaction that contained
1:1 equimolar mixture of both allelomorphs (ﬁlled circle). In (A) and
(B), the solid lines represent non-linear, least square ﬁts using the
equation described in Section 2.
Fig. 5. Eﬀect of the polymorphic residue at position 129 on the
kinetics of seeded amyloid formation of recombinant human PrP90–231
measured by ThT ﬂuorescence. (A) Comparison of the time-dependent
change in ThT ﬂuorescence between the two PrP allelomorphs during
homologous seeding; Met129 in presence of 1% Met129 seed (empty
squares) and, Val129 in presence of 1% Val129 seed (empty triangles).
(B) Comparison of the time-dependent change in ThT ﬂuorescence
between the two PrP allelomorphs during heterologous seeding;
Met129 in presence of 1% Val129 seed (empty squares) and, Val129
in presence of 1% Met129 seed (empty triangles). The amyloid reaction
was performed at 37 C under continuous agitation. The proteins were
diluted from 6 M guanidine hydrochloride to a ﬁnal concentration of
35 lM in phosphate buﬀered saline, pH 7.2, containing 1 M guanidine
hydrochloride, 3 M urea, 0.02% azide and 1% of the corresponding
amyloid seed. In (A) and (B), the solid lines represent non-linear, least
square ﬁts to the data using Eq. (1) described in Section 2.
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codon 129 on the kinetics of amyloid accumulation [10]. In-
stead, our ﬁndings indicate that the polymorphism at codon
129 of human PrP can exert its eﬀect on the misfolding path-
way that leads to amyloid accumulation only when PrP is in
a partially disordered state. Furthermore, the relative ease with
which the a-monomeric forms of PrP allelomorphs can transi-
tion to the amyloid state indicates that this process is relatively
insensitive to the local, native conformational subtleties that
might be conferred by the codon 129 polymorphism [10]. This
is consistent with the ﬁnding that the solution structures and
dynamic stabilities of recombinant human PrP are not aﬀected
by this polymorphism [13]. Since the eﬀect of the polymor-
phism at codon 129 on the kinetics of amyloid formation
seems to be dependent on the initial folding state of PrP, one
could speculate that the residues involved in the initiation of
the process, or even those that are participating structurally,
may diﬀer between pathway 3 and pathway 4 of amyloid for-
mation (Fig. 1). Taken together our data strongly support a
model, which postulates that: (i) the thermodynamic character
of the native and denatured ensembles of PrP is variable and
gradually changes with environment; (ii) the variable character
of the native/denatured ensemble determines the diversity of
misfolding pathways under diﬀerent initial solvent conditions
[20]. A direct implication of this would be that the amyloid
formed under diﬀerent pathways might diﬀer slightly in their
three-dimensional structure. Whether they also diﬀer in their
toxicity and infectivity, the question remains to be answered.
Taken together, our studies demonstrate the complexity and
the profound eﬀect that the polymorphic residue at position
129 can have on the misfolding pathways of human PrP. These
data are in contrast with the observations made during the
misfolding into oligomers, where the amount of oligomer seen
with Met129 was much higher than with Val129 [9]. This fur-
ther indicates that amyloid formation occurs through a path-
way diﬀerent from the one that leads to the oligomer,
strengthening the previous ﬁnding that the b-sheet-rich oligo-
mer is not on the kinetic pathway to amyloid formation and
cannot be regarded as a substructure of the ﬁbrillar form [8].
The observed diﬀerences in the kinetics of amyloid forma-
tion allow us to deﬁne precisely one of the regions involved
in the rate-determining step of the aggregation process; the res-
idue expressed at position 129 in this regard is critical. Our
data show that the presence of a high b-sheet forming amino
acid, such as valine [21,22] at position 129 accelerated the
kinetics of amyloid formation and is consistent with molecular
dynamics simulations [23]; providing a possible molecular
mechanism for the faster nucleation rate of the Val129 variant
relative to that of the Met129 variant. Residue 129 is within the
ﬁrst b-strand (residues 128–131) in human PrP. Riek et al. [24]
proposed that this short b-sheet might be a nucleation site for
a conformational transition from PrPC to PrPSc that could in-
clude the loops connecting the b-sheet to the ﬁrst helix. Molec-
ular dynamics simulations of Syrian hamster PrP90–231 at
neutral pH showed that when valine was present at position
Fig. 6. Transmission electron micrographs and FTIR spectra of amyloids produced from recombinant human PrP90–231 allelomorphs. (A) is
representative micrograph of Met129 variant. (B) is representative micrograph of Val129 variant and (C), is a representative micrograph of the
mixture 1:1 of Met129 and Val129 variants. Aliquots of 3 ll were taken from samples containing amyloids as judged from ThT ﬂuorescence, loaded
onto carbon-coated, glow-discharged 400-mesh copper grids, blotted, negatively stained with 1% uranyl acetate, air dried and then viewed in a Zeiss
(formerly Leo) Omega 912 electron microscope equipped with an in column charge-coupled device camera (2048 · 2048 pixels) from Proscan,
Germany. The negative staining was performed on amyloid ﬁbres derived from spontaneous amyloid reactions. (D, E) FTIR spectra and second
derivatives, respectively, of the amyloid ﬁbres produced from Met129 (solid line) and Val129 (dashed line) variants.
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129 instead of methionine additional b-strands may form
involving residues 115–116 and 119–122. For the valine allelo-
morph, the percentage of molecules calculated to adopt this
structure was 23% as opposed to 0% for the methionine allelo-
morph [23], but simulations also indicated that this does not
aﬀect thermodynamic stability, as has been found experimen-
tally [11].
Using recombinant prion protein, we clearly demonstrate
that the polymorphism at codon 129 in the PrnP gene impacts
on the complexity of the misfolding pathways that lead to non-
native isoforms of prion protein. We have attempted to model
the heterozygote genotype at this polymorphic site, by analy-
sing abnormal folding pathway 4 (Fig. 1) in a 1:1 mixture of
Met129 and Val129. The results showed intermediate behav-
iour with no obvious predominant eﬀect of one variant over
the other. The fact that we do not observe biphasic behaviour
in the kinetics of amyloid formation seems to indicate that
there is a certain degree of interaction between the two allelo-
morphs. This is supported by the compatibility of seeds in the
cross-seeding experiments. Interestingly, this compatibility
seems to be 100% if one judges only from the length of the
lag phase in cross-seeding experiments. However, in terms of
the rate of growth, the two allelomorphs seem to display par-
tial compatibility, because the rate of growth is slower in cross-
seeded reactions, relative to that in spontaneous self-seeded
experiment. This indicates that the interactions between the
two variants during the higher order folding processes are
more complex than originally anticipated and warrants further
investigation. The seeding experiments also show that the
Val129 seeds are better seeds than the Met 129 seeds. We do
not have a clear explanation for this behaviour. This may be
attributed to the presence of more ends in the Val129 seeds
that are available for polymerization or it could be due to sub-
tle structural diﬀerences in the amyloid seeds that are intrinsic
to the two variants.
We have used partially denaturing conditions in these in vi-
tro conversion experiments. Although, these conditions seem
far from physiological, they may approximate an environment
leading to the formation of PrPSc. It is commonly accepted
that conversion of PrPC to PrPSc requires certain degree of
unfolding of PrPC. Several classes of molecules such as lipid
membrane [25], salt [26] and some natural nucleic acids
[27,28] were found to be capable of assisting the conversion
of PrPC into disease-related conformation by reducing thermo-
dynamic stability of PrPC and facilitating its unfolding. Chem-
ical-induced denaturation used in our study, represent more
generic way for shifting dynamic balance between native vs.
unfolded states of PrPC. Therefore, our experiments illustrate
intrinsic propensity of human PrP to convert into amyloid
forms and the dependence of this process on the polymorphism
at codon 129.
The converse propensities of the Met129 and Val129 allelo-
morphs to fold into the b-oligomer and amyloid forms, respec-
tively, is highly suggestive, given the eﬀect of the
polymorphism on disease susceptibility in vivo. We note that
neither the b-oligomers nor the amyloids perfectly reﬂect the
biophysical properties of PrPSc, the form traditionally associ-
ated with prion infectivity [16,29]. Speciﬁcally, the relative
resistance of PrPSc to digestion with proteinase K is shown
by the b-oligomer [9] but only partially by the amyloid [8],
whereas the morphological appearance and dye-binding char-
acteristics of PrPSc are reﬂected by the in vitro-formed amyloid
but not by the b-oligomer form. Our recent studies, however,
demonstrated that amyloids produced under partially denatur-
ing conditions are biochemically similar to the minor popula-
tion of PrPSc identiﬁed in patient with sporadic CJD [20].
The formation of amyloids in vitro also displays a species bar-
rier, one of the key features of prion replication [30]. Further-
more, ﬁbrilar form of PrP has an epitope presentation similar
to that of PrPSc [8].
The diﬀerences in the misfolding behaviour between Met129
and Val129 could form the basis to explain certain aspects of
human TSEs, particularly sporadic CJDs, that are associated
with codon 129 variations such as age at onset of the disease
and incubation time [6,31–35]. Reports mainly suggested that
the age at onset is lower and the disease duration longer in
Val129 cases. This eﬀect appears to be replicated in animal
models of human disease: two out of three transgenic mice
expressing human PrP Val129 showed a shorted incubation
period [36] as compared with transgenic mice expressing hu-
man PrP Met129 [37] (and Jean Manson, personal communi-
cation) when challenged with a matching genotype inocula.
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